Tesamorelin

Mechanism

Tesamorelin is full-length human GRF(1-44) carrying a trans-3-hexenoyl group on the N-terminal tyrosine. That single acyl modification is the whole design: it sterically blocks dipeptidyl peptidase-4 from cleaving the Tyr1-Ala2 bond, the reaction that destroys native GHRH within minutes of secretion. The peptide is otherwise identical to the endogenous hormone. It binds the GHRH receptor on pituitary somatotrophs, signals through Gs and cAMP to protein kinase A and CREB, and produces both immediate growth hormone release and sustained transcription of the GH1 gene.

The therapeutic logic in HIV lipodystrophy is specific and worth understanding, because it explains why tesamorelin works for that indication and why extrapolating it to general fat loss is unwarranted. People on long-term antiretroviral therapy often develop a blunted growth hormone axis alongside a characteristic redistribution of fat into the visceral compartment. Visceral adipose tissue is unusually rich in growth hormone receptors and unusually lipolytic in response to growth hormone signalling, so restoring pulsatile growth hormone output preferentially mobilises visceral rather than subcutaneous fat. Because tesamorelin acts through the pituitary, the somatostatin brake and IGF-1 feedback remain intact, which is what distinguishes it from giving recombinant growth hormone directly. The latter was tried in this population and produced greater fat loss but higher rates of glucose intolerance. Tesamorelin's short half-life, once seen as a limitation, turns out to serve this purpose: each daily injection produces a discrete secretory episode rather than continuous receptor occupancy.

What the research shows

The pivotal evidence is two multicentre, double-blind, placebo-controlled phase 3 trials in adults with HIV and excess abdominal fat, first reported by Falutz and colleagues in the New England Journal of Medicine in 2007 (412 participants randomised to daily subcutaneous tesamorelin 2 mg or placebo for 26 weeks) and subsequently pooled across 816 participants with safety extension data to 52 weeks. Tesamorelin significantly reduced visceral adipose tissue measured by CT and reduced trunk fat, with improvements in triglycerides and total cholesterol. Subcutaneous fat and lean mass were largely preserved, and there was no significant deterioration in glucose parameters over the blinded period, the finding that separated it from recombinant growth hormone in this population. Effects reversed on discontinuation, meaning treatment is suppressive rather than curative. This is a genuinely replicated, adequately powered evidence base, which is rare in this class.

Two further lines of independent work extend the picture without changing the approved indication. Stanley and colleagues ran a randomised, double-blind, multicentre trial of 61 people with HIV and non-alcoholic fatty liver disease; over twelve months tesamorelin reduced hepatic fat fraction by an absolute 4.1 per cent and a relative 37 per cent versus placebo, with 35 per cent of treated participants dropping below the 5 per cent steatosis threshold compared with 4 per cent on placebo, and less fibrosis progression. Separately, Baker and colleagues randomised 152 older adults, 66 of them with mild cognitive impairment, to twenty weeks of tesamorelin 1 mg daily or placebo; 137 completed. Executive function improved significantly (P=0.005) while verbal memory showed only a non-significant trend (P=0.08), so the honest reading is a single positive signal on one cognitive domain, not a broad cognitive benefit. IGF-1 rose 117 per cent and body fat fell 7.4 per cent, and mild adverse events were more common on drug (68 versus 36 per cent). That cognition result has not been replicated in a confirmatory trial and should not be read as establishing a cognitive indication. The honest summary is that tesamorelin has strong, replicated evidence for one specific problem in one specific population, promising single-trial evidence in two others, and no evidence at all as a general body-composition or performance agent in healthy people, a use for which it has never been tested and is not approved.

Evidence assessment

Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.

Key studies

Safety

Tesamorelin has the only real safety database in this class, drawn from 816 randomised participants followed for up to 52 weeks. The commonest adverse reactions in the placebo-controlled phase were arthralgia, injection-site erythema, injection-site pruritus, pain in the extremities, peripheral oedema and myalgia, a profile consistent with growth hormone axis activation. The labelled warnings deserve to be read as genuine class hazards rather than boilerplate: increased risk of neoplasms (tesamorelin is contraindicated in active malignancy and should be stopped if one develops, since elevated IGF-1 may promote growth of existing tumours), elevated IGF-1 requiring monitoring, fluid retention, and glucose intolerance or new-onset diabetes. There is also a general growth hormone class warning about increased mortality in acutely critically ill patients. Antibodies to tesamorelin develop in a substantial proportion of treated patients, though generally without loss of efficacy. Two points bear emphasis for readers outside the approved population. The safety data were generated in people with HIV lipodystrophy, mostly in their forties and fifties, on stable antiretroviral therapy; they do not automatically transfer to healthy adults using the compound for cosmetic fat loss. And a great deal of the tesamorelin circulating outside prescription channels is not the approved product but unregulated material sold as 'research use only', with no verified identity, purity, sterility or endotoxin testing.

Regulatory status

Questions